Karnofsky performance status as a predictive factor for cancer-related fatigue treatment with astragalus polysaccharides (PG2) injection-A double blind, multi-center, randomized phase IV study

Cheng Hsu Wang, Cheng Yao Lin, Jen Shi Chen, Ching Liang Ho, Kun Ming Rau, Jo Ting Tsai, Cheng Shyon Chang, Su Peng Yeh, Chieh Fang Cheng, Yuen Liang Lai

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fatigue is a common and debilitating symptom in patients with advanced cancer, resulting in poor quality of life and reduced treatment efficacy. Phytotherapeutic agents have shown potential effects to relieve cancer-related fatigue in these patients. The aim of this study was to evaluate the efficacy and safety of Astragalus Polysaccharides injection and identify predictive factors associated with this treatment. Patients with advanced cancer receiving palliative care with moderate to severe cancer-related fatigue were enrolled in this study for two treatment cycles. Fatigue improvement response rates were analyzed as the primary endpoint at the end of the first cycle to determine treatment efficacy. The drug safety profile was evaluated by the reporting of adverse events. Three hundred and ten patients were enrolled in this study and 214 patients were included ITT population. Improvement in fatigue scores by at least 10% was observed in greater than 65% of subjects after one treatment cycle compared to scores at baseline. Patients with higher Karnofsky Performance Status (KPS) responded better to the Astragalus Polysaccharides injection. Drug-related adverse event rates were less than 9%. This study identified KPS as a promising predictive factor for the therapeutic efficacy of Astragalus Polysaccharides injection.

Original languageEnglish
Article number128
JournalCancers
Volume11
Issue number2
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Karnofsky Performance Status
Second Primary Neoplasms
Fatigue
Polysaccharides
Injections
Neoplasms
Safety
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Palliative Care
Quality of Life
Pharmaceutical Preparations
Population

Keywords

  • Astragalus polysaccharides
  • Cancer
  • Fatigue
  • KPS
  • Palliative care

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Karnofsky performance status as a predictive factor for cancer-related fatigue treatment with astragalus polysaccharides (PG2) injection-A double blind, multi-center, randomized phase IV study. / Wang, Cheng Hsu; Lin, Cheng Yao; Chen, Jen Shi; Ho, Ching Liang; Rau, Kun Ming; Tsai, Jo Ting; Chang, Cheng Shyon; Yeh, Su Peng; Cheng, Chieh Fang; Lai, Yuen Liang.

In: Cancers, Vol. 11, No. 2, 128, 01.01.2019.

Research output: Contribution to journalArticle

Wang, Cheng Hsu ; Lin, Cheng Yao ; Chen, Jen Shi ; Ho, Ching Liang ; Rau, Kun Ming ; Tsai, Jo Ting ; Chang, Cheng Shyon ; Yeh, Su Peng ; Cheng, Chieh Fang ; Lai, Yuen Liang. / Karnofsky performance status as a predictive factor for cancer-related fatigue treatment with astragalus polysaccharides (PG2) injection-A double blind, multi-center, randomized phase IV study. In: Cancers. 2019 ; Vol. 11, No. 2.
@article{4bcd479feb1a4600add2487a362a9e97,
title = "Karnofsky performance status as a predictive factor for cancer-related fatigue treatment with astragalus polysaccharides (PG2) injection-A double blind, multi-center, randomized phase IV study",
abstract = "Fatigue is a common and debilitating symptom in patients with advanced cancer, resulting in poor quality of life and reduced treatment efficacy. Phytotherapeutic agents have shown potential effects to relieve cancer-related fatigue in these patients. The aim of this study was to evaluate the efficacy and safety of Astragalus Polysaccharides injection and identify predictive factors associated with this treatment. Patients with advanced cancer receiving palliative care with moderate to severe cancer-related fatigue were enrolled in this study for two treatment cycles. Fatigue improvement response rates were analyzed as the primary endpoint at the end of the first cycle to determine treatment efficacy. The drug safety profile was evaluated by the reporting of adverse events. Three hundred and ten patients were enrolled in this study and 214 patients were included ITT population. Improvement in fatigue scores by at least 10{\%} was observed in greater than 65{\%} of subjects after one treatment cycle compared to scores at baseline. Patients with higher Karnofsky Performance Status (KPS) responded better to the Astragalus Polysaccharides injection. Drug-related adverse event rates were less than 9{\%}. This study identified KPS as a promising predictive factor for the therapeutic efficacy of Astragalus Polysaccharides injection.",
keywords = "Astragalus polysaccharides, Cancer, Fatigue, KPS, Palliative care",
author = "Wang, {Cheng Hsu} and Lin, {Cheng Yao} and Chen, {Jen Shi} and Ho, {Ching Liang} and Rau, {Kun Ming} and Tsai, {Jo Ting} and Chang, {Cheng Shyon} and Yeh, {Su Peng} and Cheng, {Chieh Fang} and Lai, {Yuen Liang}",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/cancers11020128",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Karnofsky performance status as a predictive factor for cancer-related fatigue treatment with astragalus polysaccharides (PG2) injection-A double blind, multi-center, randomized phase IV study

AU - Wang, Cheng Hsu

AU - Lin, Cheng Yao

AU - Chen, Jen Shi

AU - Ho, Ching Liang

AU - Rau, Kun Ming

AU - Tsai, Jo Ting

AU - Chang, Cheng Shyon

AU - Yeh, Su Peng

AU - Cheng, Chieh Fang

AU - Lai, Yuen Liang

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Fatigue is a common and debilitating symptom in patients with advanced cancer, resulting in poor quality of life and reduced treatment efficacy. Phytotherapeutic agents have shown potential effects to relieve cancer-related fatigue in these patients. The aim of this study was to evaluate the efficacy and safety of Astragalus Polysaccharides injection and identify predictive factors associated with this treatment. Patients with advanced cancer receiving palliative care with moderate to severe cancer-related fatigue were enrolled in this study for two treatment cycles. Fatigue improvement response rates were analyzed as the primary endpoint at the end of the first cycle to determine treatment efficacy. The drug safety profile was evaluated by the reporting of adverse events. Three hundred and ten patients were enrolled in this study and 214 patients were included ITT population. Improvement in fatigue scores by at least 10% was observed in greater than 65% of subjects after one treatment cycle compared to scores at baseline. Patients with higher Karnofsky Performance Status (KPS) responded better to the Astragalus Polysaccharides injection. Drug-related adverse event rates were less than 9%. This study identified KPS as a promising predictive factor for the therapeutic efficacy of Astragalus Polysaccharides injection.

AB - Fatigue is a common and debilitating symptom in patients with advanced cancer, resulting in poor quality of life and reduced treatment efficacy. Phytotherapeutic agents have shown potential effects to relieve cancer-related fatigue in these patients. The aim of this study was to evaluate the efficacy and safety of Astragalus Polysaccharides injection and identify predictive factors associated with this treatment. Patients with advanced cancer receiving palliative care with moderate to severe cancer-related fatigue were enrolled in this study for two treatment cycles. Fatigue improvement response rates were analyzed as the primary endpoint at the end of the first cycle to determine treatment efficacy. The drug safety profile was evaluated by the reporting of adverse events. Three hundred and ten patients were enrolled in this study and 214 patients were included ITT population. Improvement in fatigue scores by at least 10% was observed in greater than 65% of subjects after one treatment cycle compared to scores at baseline. Patients with higher Karnofsky Performance Status (KPS) responded better to the Astragalus Polysaccharides injection. Drug-related adverse event rates were less than 9%. This study identified KPS as a promising predictive factor for the therapeutic efficacy of Astragalus Polysaccharides injection.

KW - Astragalus polysaccharides

KW - Cancer

KW - Fatigue

KW - KPS

KW - Palliative care

UR - http://www.scopus.com/inward/record.url?scp=85061976720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061976720&partnerID=8YFLogxK

U2 - 10.3390/cancers11020128

DO - 10.3390/cancers11020128

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

M1 - 128

ER -